In AID-overexpressing hematopoietic cancer cells, however, AID interacts with and stabilizes DNMT1, which blocks the anticancer effect of Zeb due to its inability to downregulate AID and hinders DNMT1 degradation. This evidence concerns the gene AICDA and hematopoietic and lymphoid cell neoplasm.